GlassScriptPhysician profile
Jennifer Iris James
NPI 1801156609
$1,557.94
in general payments reported to CMS, 2019-2025
22 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $99.45 · 2021: $193 · 2022: $81.88 · 2023: $183 · 2024: $260 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $321.16 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $278.87 | 2021-2025 | |
| Smith+Nephew, INC. | $163.00 | 2019-2020 | |
| Histosonics, INC. | $150.00 | 2025 | |
| Glaxosmithkline, LLC. | $112.74 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $90.48 | 2019-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $77.63 | 2019-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Kowa Pharmaceuticals America, INC. | $45.25 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $38.93 | 2019 | |
| Aimmune Therapeutics, INC. | $35.83 | 2025 | Vowst, Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.66 | 2021-2022 | |
| Pfizer INC. | $34.43 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $32.16 | 2024 | Nuzyra |
| Organogenesis INC. | $30.36 | 2019 | |
| Eisai INC. | $15.85 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $15.29 | 2020 | |
| Novo Nordisk INC | $15.27 | 2019 | |
| Melinta Therapeutics, LLC | $15.23 | 2019 | |
| Insulet Corporation | $15.05 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.64 | 2022 | |
| Amgen INC. | $11.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.